| | Author(s) | Sample size (experimental/control) | Time frame (y) | Contrast drugs | Duration | Outcome measures |
| | Chen et al. (2020) | 15/15 | 2020.1–2020.3 | XBJ vs. CD | 14 days | Clinical effect, CRP, adverse reactions. | | Cheng et al. (2020) | 51/51 | 2020.1.1–2020.1.30 | LHQW vs. CD | 7 days | CT, fever, cough, fatigue, expectoration, shortness of breath, chest distress, nausea, inappetence, muscle soreness, exacerbation rate. | | Duan et al. (2020) | 82/41 | 2020.2.1–2020.2.5 | JHQG vs. CD | 5 days | Fever, cough, fatigue, expectoration, rhinobyon, rhinorrhea, sore throat, nausea, diarrhea, emesis, muscle soreness, exacerbation rate, adverse reactions. | | Fang et al. (2020) | 42/41 | 2020.1.28–2020.3.31 | LHQW vs. CD | NR | Fever, cough, expectoration, shortness of breath, rhinobyon, rhinorrhea, muscle soreness. | | Guo et al. (2020) | 16/16 | 2020.1.20–2020.3.11 | XBJ vs. CD | NR | CT, fever, cough, fatigue, expectoration, diarrhea, CRP, WBC. | | Hu et al. (2020) | 142/142 | 2020.2.2–2020.2.15 | LHQW vs. CD | 14 days | Clinical effect, CT, exacerbation rate, adverse reactions. | | Li and Zhang (2020) | 6/6 | 2020.2–2020.3 | QFPD vs. CD | 6 days | Clinical effect, WBC, adverse reactions. | | Li et al. (2020) | 30/30 | 2020.1.24–2020.3.7 | QFPD vs. CD | NR | Clinical effect, exacerbation rate, adverse reactions. | | Luo et al. (2021) | 29/28 | 2020.2.16–2020.3.25 | XBJ vs. CD | 14 days | Exacerbation rate, adverse reactions. | | Lv et al. (2020) | 63/38 | 2020.1.1–2020.1.27 | LHQW vs. CD | 10 days | Fever, cough, fatigue, expectoration, shortness of breath, chest distress, rhinobyon, rhinorrhea, sore throat, nausea, diarrhea, emesis, inappetence, muscle soreness, headache, exacerbation rate, adverse reactions. | | Wen et al. (2020) | 20/20 | 2020.1–2020.3 | XBJ vs. CD | 7 days | NANR, CRP, WBC, exacerbation rate. | | Xiong et al. (2020) | 22/20 | 2020.1.30–2020.2.10 | XFBD vs. CD | 7 days | Fever, cough, fatigue, shortness of breath, chest distress, sore throat, nausea, diarrhea, emesis, inappetence, headache. | | Xu et al. (2020) | 26/26 | 2020.1.29–2020.2.28 | LHQW vs. CD | 7 days | CT. | | Yao et al. (2020) | 21/21 | 2020.1.11–1.30 | LHQW vs. CD | NR | Fever, cough, fatigue, expectoration, shortness of breath, chest distress, rhinobyon, rhinorrhea, sore throat, nausea, diarrhea, emesis, inappetence, muscle soreness, headache. | | Yu et al. (2020) | 147/148 | 2020.2.17–2020.3.6 | LHQW vs. CD | 7 days | Clinical effect, CT, CRP, exacerbation rate. | | Zeng et al. (2020) | 104/125 | 2019.12–2020.3 | QFPD vs. CD | NR | CT, adverse reactions. | | Zhang et al. (2020) | 22/22 | 2020.1.21–2020.2.24 | XBJ vs. CD | 7 days | Clinical effect, CT, NANR, adverse reactions. | | Zhao et al. (2021) | 204/204 | 2020.2.13–3.7 | HSBD vs. CD | 7 days | Exacerbation rate. |
|
|
Abbreviations: CD, chemical drugs; CRP, C-reactive protein; HSBD, Hua-Shi-Bai-Du; JHQG, Jin-Hua-Qing-Gan; LHQW, Lian-Hua-Qing-Wen; NANR, nucleic acid negative rate; NR, not reported; QDPD, Qing-Fei-Pai-Du; WBC, white blood cell; XBJ, Xue-Bi-Jing; XFBD, Xuan-Fei- Bai-Du.
|
